Exosomes Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

DelveInsight's Exosomes Pipeline Insight 2022 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape

It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Exosomes Pipeline Report
• DelveInsight's Exosomes Pipeline analysis depicts the space with 50+ active players working to develop 50+ pipeline therapies.
• The Exosomes pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
• Exosomes Pipeline companies includes Direct Biologics, Codiak BioSciences, ExoCyte Therapeutics, Avalon GloboCare, United Therapeutics Corporation, Capricor Therapeutics, Azymus Therapeutics, Versatope Therapeutics, Lamellar Biomedical, Celltrion, and many others
• The promising Exosomes therapies in the pipeline includes 1X level of MSCs-Exo, ExoIntelliScore Prostate, 2X level of MSCs-Exo, and many others.

To know more about the Exosomes Pipeline report, click here: https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exosomes Overview
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)-an intermediate endocytic compartment-with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB-a type of intraluminal vesicles (ILV's)-buds inward into the endosomal lumen.

Exosomes, produced in endosomal compartment of most eukaryotic cells, are released in the form of ILV's in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV's) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.

DelveInsight's Exosomes Pipeline Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Exosomes Emerging Drugs
• Neural exosomes (AB126): ArunA Biomedical
ArunA Biomedical's proprietary neural exosomes cross the blood-brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system's self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.

• ExoPr0: ReNeuron
Company's CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.

• exoIL-12: Codiak Biosciences
exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak's proprietary scaffold protein, PTGRFN. Developed via Codiak's proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak's preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.

Download the Exosomes Pipeline Report to learn more about the emerging Exosomes therapies at @ https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exosomes Pipeline Therapeutic Analysis
There are approx. 50+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.

Exosomes Pipeline Report provides insights into:-
• All of the companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Exosomes
• Exosomes key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Exosomes

The Exosomes Pipeline Report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Table of Content
Introduction
1. Executive Summary
2. Exosomes: Overview
3. Formation
4. Exosomes in CNS Disease
5. Exosomes in Oncology
6. Exosomes in Other Diseases
7. Pipeline Therapeutics
8. Therapeutic Assessment
9. Exosomes - DelveInsight's Analytical Perspective
10. In-depth Commercial Assessment
11. Exosomes Collaboration Deals
12. Mid Stage Products (Phase I/II)
13. MPCs-derived exosomes: Cellular Biomedicine Group Ltd.
14. AGLE 102: Aegle Therapeutics
15. Pre-clinical and Discovery Stage Products
16. exoSTING: Codiak BioSciences
17. AVA 201: Avalon GloboCare
18. UNEX 42: United Therapeutics Corporation
19. CAP 2003: Capricor Therapeutics
20. AB 126: ArunA Biomedical
21. Inactive Products
22. Exosomes Key Companies
23. Exosomes Key Products
24. Exosomes- Unmet Needs
25. Exosomes- Market Drivers and Barriers
26. Exosomes- Future Perspectives and Conclusion
27. Exosomes Analyst Views
28. Exosomes Key Companies
29. Appendix

Download Sample PDF Report for Exosomes clinical trials advancements @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.